Spruce Biosciences, Inc. (SPRB) closed at $70.50, marking a 31.1% increase over the past four weeks. Wall Street analysts have set a mean price target of $198.25, suggesting an upside potential of 181.2%. The price targets range from $140.00 to $283.00, with a standard deviation of $61.58.
Over the last 30 days, two analysts have raised their earnings estimates for SPRB, resulting in a consensus estimate increase of 29.3%. Currently, SPRB holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates.
Despite the optimistic price target, analysts caution that relying solely on these figures for investment decisions can be misleading. The correlation between earnings estimate revisions and stock price movements is noted as a more reliable indicator of potential upside.
